With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...

Vertex’s CF sales continue to grow, driven by Trikafta/Kaftrio, which added $10.24 billion in product sales in 2024. Sales of the drug were up about 15% year over year, driven by its continued robust ...

For the full year 2024, Vertex disclosed product revenue of $11.02 billion, up 12% year-over-year. The revenue growth was primarily driven by the continued performance of TRIKAFTA/KAFTRIO.

In Q4 and full year 2024, TRIKAFTA/KAFTRIO - the drug is known as TRIKAFTA in the US, and KAFTRIO in Europe — earned $2.91bn and $10.24bn of revenues, up ~15% and ~12% respectively year-on-year.

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX stock over the recent years has been far from consistent, and has ...

Vertex also presented the interim analysis (IA) of a registry-based study of real-world data collected from people with CF initiating TRIKAFTA ® from 2019-20 in the U.S. and KAFTRIO ® plus ...

However, higher Trikafta/Kaftrio sales are likely to have caused sales erosion of Vertex’s other CF drugs. While CF remains the main area of focus, the company saw rapid success in its non-CF ...